prostate cancer

[Expert Opinion on Pharmacotherapy] The authors discuss androgen deprivation therapy (ADT) history, use of leuprolide, degarelix, and relugolix, with contextual use of ADT in combination with androgen-signaling inhibitors and potential mechanisms of resistance.

[Journal of Experimental & Clinical Cancer Research] Various mechanisms of resistance have been identified including the development of androgen receptor-independent aggressive variant prostate cancer based on neuroendocrine transdifferentiation (NED). Scientists review the highly complex processes contributing to NED.

[Veru, Inc.] Veru, Inc. announced that it has entered into a clinical trial collaboration and supply agreement with Eli Lilly and company which will evaluate the efficacy and safety of enobosarm in combination with Lilly’s abemaciclib as a second line therapy in the treatment of AR+ER+HER2- metastatic breast cancer

[Telix Pharmaceuticals Limited] Telix Pharmaceuticals Limited is pleased to announce that the first patient has been dosed in the company’s prostate-specific membrane antigen targeting ‘ProstACT’ therapeutic program, which is exploring TLX591 in areas of unmet medical need across the full prostate cancer treatment journey.

[Cell Death & Disease] Researchers suggested that E2F transcription factor 2-activated DLEU2 may function as a competing endogenous RNA to facilitate prostate cancer progression by targeting the miR-582-5p/SGK1 axis.

[Clinical Cancer Research] DNA-dependent kinase catalytic subunit (DNA-PK) regulation of metabolism was interrogated using pharmacological and genetic perturbation using in vitro cell models, in vivo xenografts, and ex vivo in patient-derived explants